Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary


B/E010/19: Enterprise Support Scheme of Innovation & Technology Fund (for 2 years)
RV2018-RAF01: Regulatory affairs fund from Biomedical Technology Cluster of HK Science Park (half year)
Both require matching fund

Location: Seattle | Hong Kong | Guangzhou | Sydney | Singapore

Copyright©2023 Arbele All Rights Reserved.

error: Content is protected !!